ATE526987T1 - Dr5-antikörper und deren verwendung - Google Patents

Dr5-antikörper und deren verwendung

Info

Publication number
ATE526987T1
ATE526987T1 AT06734171T AT06734171T ATE526987T1 AT E526987 T1 ATE526987 T1 AT E526987T1 AT 06734171 T AT06734171 T AT 06734171T AT 06734171 T AT06734171 T AT 06734171T AT E526987 T1 ATE526987 T1 AT E526987T1
Authority
AT
Austria
Prior art keywords
antibodies
cancer
compositions
treatment
making
Prior art date
Application number
AT06734171T
Other languages
English (en)
Inventor
Camellia Adams
Avi J Ashkenazi
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE526987T1 publication Critical patent/ATE526987T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06734171T 2005-02-02 2006-01-31 Dr5-antikörper und deren verwendung ATE526987T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64955005P 2005-02-02 2005-02-02
US11/344,564 US8029783B2 (en) 2005-02-02 2006-01-30 DR5 antibodies and articles of manufacture containing same
PCT/US2006/003577 WO2006083971A2 (en) 2005-02-02 2006-01-31 Dr5 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
ATE526987T1 true ATE526987T1 (de) 2011-10-15

Family

ID=36777882

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06734171T ATE526987T1 (de) 2005-02-02 2006-01-31 Dr5-antikörper und deren verwendung

Country Status (16)

Country Link
US (3) US8029783B2 (de)
EP (1) EP1844077B1 (de)
JP (3) JP5886509B2 (de)
KR (1) KR101297467B1 (de)
CN (1) CN101247825B (de)
AT (1) ATE526987T1 (de)
AU (1) AU2006210779B2 (de)
BR (1) BRPI0606891A2 (de)
CA (1) CA2594918C (de)
ES (1) ES2374301T3 (de)
IL (1) IL184617A (de)
MX (1) MX2007009215A (de)
NO (1) NO341791B1 (de)
NZ (1) NZ556478A (de)
RU (1) RU2458072C2 (de)
WO (1) WO2006083971A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (de) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Spezifisch an reg iv bindende antikörper
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
EP2177230A4 (de) * 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd Immunoliposom als induktor von apoptose in todesdomäne-enthaltenden rezeptor exprimierende zelle
WO2010047509A2 (ko) * 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
EP2719774B8 (de) 2008-11-07 2020-04-22 Adaptive Biotechnologies Corporation Verfahren zur Überwachung von Zuständen durch Sequenzanalyse
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
HUE029424T2 (en) 2009-01-15 2017-02-28 Adaptive Biotechnologies Corp Adaptive immunity profiling and a method for producing monoclonal antibodies
US20120070432A1 (en) * 2009-05-28 2012-03-22 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
RU2539032C2 (ru) 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
BR112012002974B1 (pt) 2009-08-11 2022-06-07 Genentech, Inc Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP2480230A4 (de) * 2009-09-24 2015-06-10 Seattle Genetics Inc Dr5-liganden-heilmittelkonjugate
CA2773515C (en) * 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
BR112012010698A2 (pt) * 2009-11-05 2016-11-29 Uab Research Foundation método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
WO2011084623A1 (en) 2009-12-16 2011-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
MX2012013144A (es) * 2010-05-14 2012-11-30 Amgen Inc Agonistas mejorados de receptor de muerte.
JP2013537414A (ja) * 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Ｉｌ−１７に対する抗体
WO2012057288A1 (ja) * 2010-10-29 2012-05-03 第一三共株式会社 新規抗ｄｒ５抗体
EP2670426B1 (de) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodale trail-moleküle und ihre verwendungen in zelltherapien
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
WO2012151317A1 (en) * 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012325791B2 (en) 2011-10-21 2018-04-05 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
ES2867924T3 (es) 2011-12-09 2021-10-21 Adaptive Biotechnologies Corp Diagnóstico de tumores malignos linfoides y detección de enfermedad residual mínima
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
EP2823060B1 (de) 2012-03-05 2018-02-14 Adaptive Biotechnologies Corporation Festlegung von gepaarten immunrezeptorketten aus frequenzabgestimmten untereinheiten
MX350202B (es) * 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
DK2831276T3 (da) 2012-05-08 2016-08-01 Adaptive Biotechnologies Corp Sammensætninger og fremgangsmåde til at måle og kalibrere amplifikations-bias i multipleks-PCR-reaktioner
US9500639B2 (en) 2012-07-18 2016-11-22 Theranos, Inc. Low-volume coagulation assay
WO2014018113A1 (en) 2012-07-24 2014-01-30 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) * 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
US20160002731A1 (en) 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
KR102180660B1 (ko) * 2013-05-03 2020-11-19 후지필름 다이오신쓰 바이오테크놀로지스 유케 리미티드 발현 방법
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
MX383206B (es) * 2013-11-25 2025-03-13 Seagen Inc Preparación de anticuerpos de cultivos de célula de ovario de hámster chino para conjugación.
AU2015227054A1 (en) 2014-03-05 2016-09-22 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP3132059B1 (de) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
AU2016205677A1 (en) * 2015-01-08 2017-07-27 Kyowa Hakko Kirin Co., Ltd. Bispecific antibody binding to TRAILR2 and PSMA
EP3750918A1 (de) * 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumornekrosefaktor-superfamilienrezeptorbindende moleküle und verwendungen davon
AR100680A1 (es) * 2015-01-26 2016-10-26 Macrogenics Inc Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
ES2858306T3 (es) 2015-02-24 2021-09-30 Adaptive Biotechnologies Corp Método para determinar el estado de HLA mediante secuenciación del repertorio inmunitario
EP3277294B1 (de) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Verfahren zur identifizierung von menschlichen kompatiblen t-zell-rezeptoren spezifisch für ein antigen-ziel
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017028279A1 (en) * 2015-08-19 2017-02-23 Beijing Cotimes Biotech Company Limited Trail receptor-binding agents and uses of same
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368076B1 (de) * 2015-10-30 2025-04-30 Galaxy Biotech, LLC An death-rezeptor 4 und 5 bindende hochwirksame antikörper
JP6797203B2 (ja) 2015-12-17 2020-12-09 ザ・ジョンズ・ホプキンス・ユニバーシティー デスレセプターアゴニストによる全身性硬化症の改善
US10849912B2 (en) 2016-02-09 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3360898A1 (de) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
JP7245793B2 (ja) 2017-06-30 2023-03-24 ザイムワークス ビーシー インコーポレイテッド 安定化したキメラＦａｂ
KR101951025B1 (ko) 2017-08-17 2019-02-21 서울대학교산학협력단 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
WO2019100193A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
CN109810194B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
WO2019100194A1 (zh) * 2017-11-21 2019-05-31 深圳先进技术研究院 抗dr5的抗体及其制备方法和应用
CN109810193B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
CN109957025A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
GB201800994D0 (en) * 2018-01-22 2018-03-07 Ucl Business Plc Combination therapeutics
WO2019173499A1 (en) 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer
WO2019238143A2 (zh) * 2018-06-13 2019-12-19 北京吉尚立德生物科技有限公司 结直肠癌实体瘤原代细胞和结直肠癌腹水原代肿瘤细胞培养方法及配套试剂
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
US20240382499A1 (en) 2021-01-15 2024-11-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
CN113493510A (zh) * 2021-07-07 2021-10-12 上海交通大学 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用
CN117285643A (zh) 2022-06-16 2023-12-26 清华大学 一种相变调节套件及其用途
WO2025098480A1 (zh) * 2023-11-10 2025-05-15 信达生物制药(苏州)有限公司 抗dr5和ceacam5的双特异性抗体及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025235931A2 (en) * 2024-05-09 2025-11-13 Aptamino, Llc Antibody structures comprising helical complementarity determining regions

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5278229A (en) * 1990-02-01 1994-01-11 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Polyolefin composition and the use thereof
ES2108048T3 (es) * 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0940468A1 (de) * 1991-06-14 1999-09-08 Genentech, Inc. Änderliches Gebiet einer humanisierter Antikörper
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3144193A (en) * 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
EP1005870B1 (de) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AU704440B2 (en) * 1994-02-04 1999-04-22 Bio Merieux MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
EP0939804B2 (de) 1996-10-25 2011-06-15 Human Genome Sciences, Inc. NEUTROKIN alpha
EP0944662A1 (de) 1996-12-13 1999-09-29 Du Pont-Toray Company, Ltd. Polyestercarbonat-polyurethanharnstoff faser
EP2003203A1 (de) 1996-12-23 2008-12-17 Immunex Corporation Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
ES2281126T3 (es) * 1997-03-17 2007-09-16 Human Genome Sciences, Inc. Receptor 5 que contiene un dominio de muerte.
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
AU7126498A (en) * 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
ATE516354T1 (de) * 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US5896768A (en) * 1997-05-15 1999-04-27 Ut Automotive Dearborn, Inc. Electronic child security door lock system
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
US6417328B2 (en) 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ATE411385T1 (de) 1998-01-15 2008-10-15 Genentech Inc Apo-2 ligand
US6468532B1 (en) * 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
WO1999037684A1 (en) 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
WO1999064461A2 (en) 1998-06-12 1999-12-16 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
KR101077001B1 (ko) * 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
AU781952B2 (en) 1999-05-28 2005-06-23 Genentech Inc. DR4 antibodies and uses thereof
PT1192185E (pt) 1999-06-09 2006-11-30 Genentech Inc Sinergismo de agonista do receptor de apo-2l e cpt-11
ES2392392T3 (es) 1999-06-28 2012-12-10 Genentech, Inc. Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
DE60118163T2 (de) 2000-01-20 2006-12-21 Rhodia Chimie Verfahren zur herstellung von schwach gefärbten, verzweigten polyisocyanaten und daraus resultierende zusammensetzung
JP2001259961A (ja) * 2000-03-15 2001-09-25 Disco Abrasive Syst Ltd 加工装置
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US7960670B2 (en) * 2005-05-03 2011-06-14 Kla-Tencor Corporation Methods of and apparatuses for measuring electrical parameters of a plasma process
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
JP4309758B2 (ja) 2001-05-25 2009-08-05 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
KR20040081422A (ko) 2001-11-01 2004-09-21 유에이비 리서치 파운데이션 종양 괴사 인자-관련 세포사멸-유도 리간드 수용체에선택적인 항체와 다른 치료제와의 복합물
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
AU2002352676A1 (en) 2001-11-14 2003-05-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002361784A1 (en) 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用

Also Published As

Publication number Publication date
IL184617A (en) 2013-05-30
EP1844077B1 (de) 2011-10-05
ES2374301T3 (es) 2012-02-15
JP2013027407A (ja) 2013-02-07
JP2008532487A (ja) 2008-08-21
KR20070102585A (ko) 2007-10-18
BRPI0606891A2 (pt) 2009-07-21
HK1109638A1 (en) 2008-06-13
US20120087922A1 (en) 2012-04-12
RU2007132876A (ru) 2009-03-10
US20070031414A1 (en) 2007-02-08
US20060269554A1 (en) 2006-11-30
CA2594918A1 (en) 2006-08-10
US8409570B2 (en) 2013-04-02
AU2006210779A1 (en) 2006-08-10
AU2006210779B2 (en) 2011-09-22
NO341791B1 (no) 2018-01-22
US8029783B2 (en) 2011-10-04
MX2007009215A (es) 2007-08-23
NO20074446L (no) 2007-11-01
EP1844077A4 (de) 2010-03-17
CA2594918C (en) 2014-09-02
US8030023B2 (en) 2011-10-04
WO2006083971A3 (en) 2008-04-03
JP5886509B2 (ja) 2016-03-16
WO2006083971A2 (en) 2006-08-10
CN101247825A (zh) 2008-08-20
CN101247825B (zh) 2014-01-01
RU2458072C2 (ru) 2012-08-10
EP1844077A2 (de) 2007-10-17
JP2015133985A (ja) 2015-07-27
NZ556478A (en) 2011-02-25
KR101297467B1 (ko) 2013-08-16
IL184617A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
ATE526987T1 (de) Dr5-antikörper und deren verwendung
WO2007053573A3 (en) Treatment of cancer with sorafenib
IL244803A0 (en) Human anti-beta7 antibodies and their use
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
IL258880A (en) Diarylhydantoin compounds
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2007061874A3 (en) Methods and compositions for use in treating cancer
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EP1912674B8 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
JO2576B1 (en) Antibodies
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
CY1115535T1 (el) Αναστολεις δραστικοτητας ακτ
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
IL214325A (en) Antibody against cmet, a drug that includes and uses it
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2008150530A3 (en) Cripto binding molecules
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
NZ591943A (en) Anti-tgf-beta receptor ii antibodies

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1844077

Country of ref document: EP